Patent · US Active

(Anti-HER2 antibody)-drug conjugate

US11185594B2 · kind B2 · utility

0Cited by

12References

11Claims

0Family size

Assignee

DAIICHI SANKYO COMPANY, LIMITED · JP

Inventors

Hiroyuki Naito · Tokyo, JP
Takeshi Masuda · Tokyo, JP
Takashi Nakada · Tokyo, JP
Masao Yoshida · Tokyo, JP
Shinji Ashida · Tokyo, JP
Hideki Miyazaki · Tokyo, JP
Yuji Kasuya · Tokyo, JP
Koji Morita · Tokyo, JP
Yusuke Ogitani · Tokyo, JP
Yuki Abe · Tokyo, JP

Key dates

Filing date	Apr 6, 2015
Grant date	Nov 30, 2021
Priority date	—
Expiry date	Aug 13, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/73
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the formula: L1-L2-LP-NH—(CH2)n1-La-Lb-Lc or -L1-L2-LP- wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the terminal Lc or LP with the nitrogen atom of the amino group at position 1 as the connecting position.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.